Close Menu

NEW YORK – In a new study published in the Journal of Clinical Oncology last week, researchers reported that in a Phase I trial, BeiGene's experimental RAF family kinase inhibitor lifirafenib (BGB-283) demonstrated promising activity in patients with KRAS-mutated non-small cell lung cancer and BRAF-mutated melanoma, thyroid cancer, and ovarian cancer. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

May
27
Sponsored by
Discovery Life Sciences

M2Gen’s Oncology Research Information Exchange Network (ORIEN) Avatar Research Program collects and studies consented cancer patients’ biospecimens and companion clinical information for the development of improved oncology treatments.